Chie-Schin Shih, MD, MSc
Clinical Associate Professor of Pediatrics
705 Riley Hospital Drive, ROC 4340
Indianapolis, IN 46202
Pediatric Hematology Oncology
Areas of Interest
Developmental therapeutics in Brain and Spinal cord tumors, novel diagnostic imaging techniques for brain tumors, developmental therapeutics in neurofibromatosis, palliative care.
Dr. Chie-Schin Shih is the Program Leader for the Pediatric Neuro-Oncology Program and is a pediatric hematologist/oncologist at Riley Hospital for Children/ Indiana University Health. He specializes in treating patients with brain and spinal cord tumors as well as other related neurological malignancies. He is a clinical and translational researcher with expertise in novel neurological imaging, biomarkers and developmental therapeutics. Among the projects that Dr. Shih is currently active include MRI Diffusion Tensor Imaging (DTI) in optic gliomas, Fatigue in patients receiving Proton Beam Radiotherapy, Sunitinib for the treatment of NF1 Plexiform Neurofibromas, and Cabozantinib for the treatment of plexiform neurofibromas. Dr. Shih is an active Primary Investigator in the NF Clinical Trials Consortium, and is an active member in the international Response Evaluations in Neurofibromatosis (REiNS) as well as the Children’s Oncology Group.
|1997||BS, George Washtington University School of Medicine|
|2001||MD, George Washington University School of Medicine|
|2004||Pediatric Residency, Cleveland Clinic Foundation|
|2007||Pediatric Hematology/Oncology Fellowship, St. Jude Children’s Research|
|2012||MS, Indiana University School of Medicine|
Honors & Awards
- Hyundai Hope on Wheels Scholar Award, Hyundai Hope on Wheels, 2010
- NIH Training Grant T32-CA070089, 2005
- Gill Award for Summer Research: George Washington University SOM, 1998
- BA-MD Scholarship Award: George Washington University, 1994
Riley Outpatient Center
705 Riley Hospital Drive
Indianapolis, IN 46202
Research & Grants
Dr. Shih is active in research in brain tumors and neurofibromatosis type I. He is an active member of the NF Clinical Trials Consortium and is currently the Primary Investigator in two phase II clinical trials. These trials are sponsored by the Department of Defense (DOD) and are multi-institutional involving 17 institutions throughout the US through the NF Clinical Trials Consortium. In addition, Dr. Shih is active in pediatric brain tumor research with clinical trials evaluating novel advanced MRI imaging techniques utilizing DTI in optic pathway gliomas as well as collaborating with Nationwide Children’s Hospital in the Head Start/NEXT Consortium to offer novel treatment for Infant brain tumors
*Phase II Study of Cabozantinib in NF type I Plexiform Neurofibromas in subjects >16 years of age.
Granting Agency: Department of Defense: NF Clinical Trials Consortium
Role: Primary Investigator: Multi-institutional clinical trial
*Phase II Study of Sutent, an Oral Multi-targeted Tyrosine Kinase Inhibitor in Subjects with NF-1 Plexiform Neurofibromas
Granting Agency: Department of Defense W8XWH-11-1-0137 and Pfizer WS818589
Role: Primary Investigator
Dates: 1/2012- 1/2017
*Phase 2 Trial of Nilotinib (Tasigna) in Neurofibromatosis (NF1) Patients with Plexiform Neurofibromas.
Granting Agency: Novartis Pharmaceutical Corporation CA Role: Co-Investigator
*Phase 2 Study of Everolimus (RAD001) for Children with Neurofibromatosis Type-1 and Chemotherapy-Refractory Radiographic Progressive Low-Grade Gliomas
Granting Agency: Department of Defense
Role: Institutional Primary Investigator
Phase 2 Multi-Institutional Trial of Focal Radiotherapy with Concomitant Carboplatin as a Radiosensitizer and the Prospective Analysis of Survivin, an Inhibitor of Apoptosis, as a Biomarker in Children with Newly Diagnosed Non-Metastatic Ependymoma and Minimal Residual Disease Post-Operatively
Granting Agency: Children’s Memorial Hospital (Chicago)
Dombi E, Ardern-Holmes SL, Bobovic-Vuksanovic D, Barker FG, Connor S, Evans DG, Fisher MJ, Goutagny S, Harris GJ, Jaramillo D, Karajannis MA, Korf BR, Mautner V, Plotkin SR, Poussaint TY, Robertson K, Shih CS, Widemann BC. Recommendations for imaging tumor response in neurofibromatosis clinical trials. REiNS International Collaboration. Neurology 2013 Nov 19;8(21Suppl 1):S33-40.
Shih CS, Burgett R, Bonnin J, Boaz J, Ho CY. Intracranial Masson tumor: case report and literature review. J Neurooncol. 2012 May; 108(1):211-7.
Quigg TC, Haddad NG, Buchsbaum JC, Shih CS. Hypothalamic obesity syndrome: rare presentation of CNS+B-cell lymphoblastic lymphoma. Pediatr Blood Cancer. 2012 Nov;59(5):930-3.
Shih CS, Laurie N, Holzmacher J, Spence Y, Nathwani AC, Davidoff AM, Dyer MA. AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models. Neuromolecular Med. 2009 Mar 22; 11(1):43-52.
Shih CS, Hale G, Xin T, Gronewold L, Gilger E, Srivastava D, Kun L, Gajjar A, Fouladi M. Myeloablative Chemotherapy with Autologous Bone Marrow Rescue for Children with Recurrent Malignant Brain Tumors. Cancer. 2008 Mar 15; 112(6):1345-53.
Laurie N, Shih CS, Dyer MA. Targeting MDM2 and MDMX in Retinoblastoma. Current Cancer Drug Targets. 2007 Nov7; 7(7):689-695.
Shih CS, Laurie N, Davidoff A, Dyer MA. AAV-Mediated Delivery of Interferon-? for the Treatment of Retinoblastoma in Preclinical Models. Abstract presented at ASCO 2007.
Laurie N, Donovan S, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006 Nov 2; 444(7115):45-6.
Clow LA, Gross PS, Shih CS, Smith LC. Expression of SpC3, the sea urchin complement component, in response to lipopolysaccharide. Immunogenetics. 2000 Oct; 51(12):1021-33.
Smith LC, Shih CS, Dachenhausen SG. Coelomocytes express SpBf, a homologue of factor B, the second component to sea urchin complement system. J Immunol. 1998 Dec 15; 161(12): 6784-93.